Acute Pain Management and Prevention


Age

Self-report scale

Hetero-evaluation scale

Premature and infants

n/a

PIPP-R,COMFORT

Before 3 years

n/a

FLACC

After 5–6 years

Faces, Poker Chips, NRS, VAS

FLACC, CHEOPS

Situation

PACU/ward

VAS, Faces, Poker Chips, NRS

FLACC, CHEOPS

PICU/NICU

VAS, Faces, Poker Chips, NRS

FLACC, CHEOPS, COMFORT

Children with special needs

n/a

m-FLACC, NCCPC-PV

At home

VAS, NRS (if >5–6 years)

PPMP (>2 years)


Adapted from PedIMMPACT [21]

n/a not adapted, COMFORT, PIPP-R Premature Infant Pain Profile-Revised [19], VAS visual analog scale, NRS numerical rating scale, (m-)FLACC (modified-)Face, Legs, Activity, Cry, Consolability, CHEOPS Children’s Hospital Of Eastern Ontario Pain Scale, NCCPC-PV Non-communicating Children’s Pain Checklist-Postoperative Version [20], PPPM Parents’ Postoperative Pain Measure



The child’s parents are essential members of the treatment team. In the day hospital clinical setting, they are the sole dispenser of analgesic medication once back home. Dedicated pain assessment tools have been developed for parental postoperative pain management, like the Parents’ Postoperative Pain Measure (PPPM). Unfortunately, even with such tools and correct assessment of pain condition, parents still give few analgesics medications, mainly due to fear of pain medication’s adverse effects [13, 14].

Children with special needs remain a vulnerable population at risk of poor pain control after surgery. The underpinning condition often compromises their ability to express pain. The parents of children with cognitive impairment usually develop unique abilities for the assessment of their child level of discomfort and pain [15, 16].

The use of hemodynamic parameters has not been standardized to assess the effectiveness of analgesia and hence may be prone to imprecise evaluation and decision management in the perioperative setting. However, new technologies like the Analgesia Nociception Index (ANI) and the Pupillary Reflex Dilatation (PRD) deserve a special attention as alternatives for nociception assessment during surgery. Both ANI and PRD monitor the balance between sympathetic and parasympathetic activities, either through heart rate variability or pupillary diameter evolution in response to a noxious stimulus. These technologies were used to evaluate the effectiveness of nerve block [17] and remifentanil [18] in children undergoing sevoflurane anaesthesia.



23.3 Multimodal Analgesia


The timing of the antinociceptive intervention [22] seems to be less important than the modality and duration [23, 24]. Preventive analgesia focuses on attenuating the perioperative noxious stimuli and aims to diminish perioperative pain and analgesic requirements during and after the surgical period. The key point is a judicious use of multimodal strategies, targeting different pathways of pain signalling, enhancement, or perpetuation. This may also reduce the short-term morbidity (urinary retention, constipation, nausea and vomiting, respiratory depression, etc.) as well as some long-term consequences of the acute nociceptive stimulus like the chronic postsurgical pain [25].


23.4 Control of Acute Pain



23.4.1 Opioid Analgesics (Table 23.2)





Table 23.2
Examples of dosing for currently used opioids and their routes of administration



















































































Opioid

Route

Age group

Dose/interval

Morphine

PO

Infants and children

100–250 μg/kg q3–4H

IV bolus

Preterm neonate

Full-term neonate

Infants and children

25–50 μg/kg q3–4H

50–100 μg/kg q3H

IV infusion

Preterm neonate

Full-term neonate

Infants and children

2–5 μg/kg/h

5–10 μg/kg/h

15–30 μg/kg/h

Hydromorphone

PO

Infants and children

40–80 μg/kg q4H

IV bolus

10–20 μg/kg q3–4H

IV infusion

3–5 μg /kg/h

Fentanyl

IV bolus

Infants and children

0.5–1 μg/kg q1–2H

IV infusion

0.5–2 μg/kg/h

IN

1–2 μg/kg q1–2H

Sufentanila

IV bolus

Infants and children

0.1–1 μg/kg

IV infusion

0.1–2 μg/kg/h

IN aerosol

1–2 μg/kg

Remifentanila

IV bolus

Infants and children

1–2 μg/kg

IV infusion

0.1–1 μg/kg/hb

Methadone

IV bolus

Infants and children

0.05–0.1 mg/kg

Nalbuphine

IV bolus

Infants and children

0.1–0.2 mg/kg

Tramadol

IV or PO start dose

Infants and children

1–2 mg/kg q6H (max 400 mg/day)


Adapted from the Acute Pain Guidelines of the Montreal Children’s Hospital

PO per os (orally), IV intravenous, PR per rectum (rectally), IM intramuscular, IN intranasal, q every, H or h hour, m minutes

aAdministration limited to acute care setting

bHigher infusion rates may be used for a limited time duration (possible link to opioid-induced hyperalgesia)

Opioids are an essential tool for the prevention and treatment of moderate to severe pain in children. Due to its efficacy and versatility, they have a central role in multimodal analgesia.

Whenever feasible, the oral administration should be preferred in the postoperative setting. The administration on an as-needed basis (PRN: pro re nata) may provide less clinical disponibility than on a regular basis (ATC: around the clock) or continuous infusion.

The adverse effects associated to the use of opioids varies from nausea and vomiting, pruritus or constipation to more serious like opioid-induced respiratory depression (OIRD) and opioid withdrawal after prolonged use. Opioid-naive neonates and infants are at more risk of OIRD reducing doses and increasing the administration intervals increases the opioid safety margin in those populations [26, 27]. The concomitant use of non-opioid analgesics and regional analgesia techniques further reduces opioid-related risks. An alternative management to common opioid-induced side effects is the use of naloxone at low dose as a continuous IV infusion [28].


23.4.1.1 Morphine


Morphine is a very versatile molecule, dispensable through various routes, of which PO and IV are the most used in hospitalized patients. The hydrophilic properties of morphine allow longer duration of analgesia compared to more lipophilic opioids.

The total body clearance of morphine represents 80 % of the adult range 6 months after birth and 96 % by 1 year of age [29]. Morphine undergoes hepatic metabolism and then renal excretion. Infants and premature neonates may display a large range of elimination half-life due to immaturity of the glucuronidation mechanism. Half-life may vary from 9 ± 3 h in premature neonates, 6.5 ± 2.8 h in term neonates, to 2.0 ± 1.8 h in infants and children [26, 27, 30].


23.4.1.2 Fentanyl


Fentanyl is frequently used for acute pain prevention and management during surgery. It also offers benefits in patients with renal failure or in those at risk of histamine release. Its high lipid solubility promotes fast IV or IN onset with peak of action of less than 5 min or 15 min, respectively. New dispersion formulation like oral transmucosal fentanyl citrate (OTFC) may be interesting for moderately painful procedures of short duration, when IV access is not in place or not desirable [31].

Fentanyl is commonly used as continuous infusion in PICU and NICU. Premature babies and infants are at risk of accumulation due to a reduced plasmatic clearance [32].


23.4.1.3 Sufentanil


Sufentanil is eight to ten times more potent than fentanyl. The clearance of sufentanil in normal children is twice that in adolescents; thus a greater maintenance regimen is necessary. In opposition to fentanyl, sufentanil presents less accumulation over time during continuous infusion, thus offering stable plasmatic levels with shorter half-life and less postoperative respiratory depression. Its lipophilic properties promote residual analgesia and diminished postoperative agitation in PACU.

Another advantage is its versatility of use through different routes, like intranasal. A single IN dose as premedication may cover analgesia for short and moderately painful procedures, for example, myringotomies, dressing changes, or tubes removal [33], with the combined advantage of providing preprocedural anxiolysis and sedation.


23.4.1.4 Remifentanil


Remifentanil is rapidly metabolized in the plasma by nonspecific esterases and does not accumulate with prolonged infusions [34]. Those properties allow high titratability and make remifentanil a useful molecule for short procedures with minimal post-procedural pain, like cardiac catheterization or biopsies. One drawback is the potential induction of acute opioid tolerance (AOI) and opioid-induced hyperalgesia (OIH) [35] precluding its use during a prolonged time and/or at high dose. Infusion rates between 0.1 and 0.3 mcg/kg/min seem not to induce AOI or OIH [35].


23.4.1.5 Oxycodone


Oxycodone is 1.5–2 times more potent than oral morphine and is provided in short-acting and long-lasting PO formulation. The metabolism in patients older than 6 months shows stable values and clearance 50 % higher than adults [36, 37]. Onset, peak, and duration of action are similar to those of oral morphine, thus rendering oxycodone a valid option for opioid rotation in the context of opioid-induced hyperalgesia or due to adverse effects.


23.4.1.6 Hydromorphone


Hydromorphone is commonly used in the paediatric population due to its renal elimination as an inactive metabolite and lack of histamine release [38, 39]. It is five to seven times more potent than morphine with similar onset and duration of action. Common routes of administration are IV, PO, or epidural. Hydromorphone is also a popular second-choice molecule when opioid rotation is needed. PCA mode is convenient; however one should be careful with conversion calculation and the risk of errors with small boluses.


23.4.1.7 Methadone


Methadone has been safely used for postoperative pain in children [40], burns [41], or trauma [42], by IV or PO routes. It is also frequently used for opioid rotation and treatment of opioid withdrawal syndrome due to its NMDA receptor antagonist properties [43]. The longer duration of action could represent a double-edged sword, as side effects related to over dosage would last longer. The administration of methadone in opioid-naive patient should only be initiated in a hospital setting, paying close attention to side effects and various drug interactions.

Methadone is considered a second-line opioid for acute pain management; however it could be used as a single bolus co-analgesic for procedures that are relatively painful in the first 24 h [44] like orchidopexy, as weaning from regional anaesthesia or in the context of surgery with high nociceptive impact like spinal surgery.


23.4.1.8 Nalbuphine


Nalbuphine is an agonist-antagonist semi-synthetic opioid with pharmacological potency comparable to morphine, usually indicated in procedures with minimal to moderate pain intensity. Because of its κ-receptor agonist and μ-receptor antagonist properties, the risk of respiratory depression associated with μ-receptor is prevented. The effect on the κ-receptor reduced the incidence of emergence agitation in PACU [45]. Nalbuphine has minimal effect on bowel or bladder function, characteristics of interest in ambulatory surgery. On the other hand, nalbuphine has a ceiling effect above 0.4 mg/kg, and the induced sedation may trigger upper airway obstruction.


23.4.1.9 Tramadol


Tramadol is a weak μ-opioid receptor agonist and a monoaminergic (MAO) reuptake inhibitor [46, 47]. It is derived from codeine and metabolized in the liver through the CYP2D pathway [48]. Its MAO properties may play a role in minimizing the μ side effects like constipation and especially respiratory depression [49]. This makes tramadol an alternative option in children with known risk factor for OIRD, like obstructive sleep apnoea [50]. It was associated with a similar incidence of postoperative nausea and vomiting as morphine. It has a similar safety profile either in patients with neuropathic pain and with nociceptive pain [51].

The recommended IV dose is 1 mg/kg and 100 mg is approximately equivalent to 10 mg of morphine [52, 53]. It has been effectively used by mouth, IV, IM, caudal/epidural, or local infiltration [54] as well as topical application during tonsillectomy [55]. Tramadol/acetaminophen combination is a convenient analgesic post-tonsillectomy pain control, especially at home. One consideration to rise is the theoretical risk of hypoglycemia in predisposed patients and serotoninergic syndrome with the concomitant use of selective serotonin re-uptake inhibitors.


23.4.1.10 PCA, NCA, and PARCA (Table 23.3)





Table 23.3
Example of PCA/NCA/PARCA














































































































Drug

Bolus dose (μg/kg)

Lockout time (minutes)

Basal infusion (μg/kg/h)

1 h limit (μg /kg/h)

Children >6 years and appropriate developmental/motor state

Morphine PCA

10–30

6–15

0–4–20c

100–400

Morphine + ketamine PCA (1:1)

10–30

6–15

0–4–20

100 – 400

Hydromorphone PCAa

2–6

6–15

0–1–5

20–80

Fentanyl PCAb

0.2–0.5

6–8

0–0.1–0.5

2–5

Morphine NCA

Preterm neonates

4

30

0–2–4

50

Term neonates

Infants <2 months

20

20

0–4–10

100

Ward: children >2 months

50

15

0–10–20

100–400

Morphine PARCA

Preterm neonates

n/a

n/a

n/a

n/a

Term neonates

Infants < 2 months

n/a

n/a

n/a

n/a

Ward: children >2 months

50

15

0–10–20

100–400

Hydromorphone NCA a

Preterm neonates

1

30

0–0.5–1

10

Term neonates

Infants <2 months

4

20

0–1–2

20

Ward: children >2 months

6–10

15

0–1–5

50–100

Fentanyl NCA b

Ward: Children >2 months

0.2–1

15–30

0–0.1–0.5

2–5


Adapted from APS guidelines of the Acute Pain Service of the Montreal Children’s Hospital and of the Mother and Child Hospital Lyon

PARCA parent-controlled analgesia, n/a non-applicable

aFirst line for morphine allergy; first line for renal failure; second line for morphine side effects

bFirst line for renal failure; second line for morphine side effects

c0–4–20 = either no basal infusion or between 4 and 20 μg/kg/h

The patient-controlled analgesia (PCA) gives autonomy to patients over their pain control and positively influences the latter through patient’s empowerment [56]. It is a safe alternative for pain management in children of 6 years old and older. PCA implies the understanding of the concept, the ability to self-evaluate pain, and the capacity of activate the dosing device. It is also useful in hospital “frequent flyer” children younger than 6 years of age with closer monitoring from the acute pain team.

Younger children or those unable to manipulate the machine (with special needs or physical restraint) benefit from proxy-controlled analgesia, usually the nurse in charge of the patient or a parent. A recent survey of 252 American centres [57] showed that the vast majority of centres (96 %) would provide PCA but has proxy-controlled analgesia (nurse or parent) in only 38 %. Indeed, this latter technique provides excellent pain relief for children unable to use it by themselves but may create some safety challenges given the subjectivity of the proxy, bypassing the inherent safety features of analgesics dispensed by the patient itself. The main concern is a slightly augmented incidence of respiratory depression [58], easily detected by proper monitoring and treatment without major consequences. Parent-/nurse-controlled analgesia for children with developmental delay is efficient and safe but implies a reinforced monitoring, strict education of the proxy, and clear, written, instruction [59].

The standard monitoring includes oxygen saturation and respiratory rate. More advanced measurements like continuous capnography or breathing sounds through a microphone placed on the neck may further augment safety and prevent oversedation.

The use of a background continuous infusion is controversial. The aim is to improve analgesia through an increase of the plasmatic levels of opioids, especially during night-time, when patient uses PCA less. The increased risk of respiratory adverse events may not justify the potential analgesic advantages.

An acute pain team, informed proxy or nursing staff, and an adequate monitoring increase the safety independently of the modality (PCA, NCA, or PARCA) or the risk of the patient (opioid tolerant, neonates, OSA, etc.)


23.4.2 Non-opioid Analgesics (Table 23.4)





Table 23.4
Examples dosing of non-opioid analgesics and routes of administration
















































Drug

Age group

Route/dose/interval

Max. daily dose

Acetaminophen (paracetamol)

Term infants and children:

PO: 10–15 mg/kg

q4–6H

PR: 20–40 mg/kg q6H

Children <100 mg/kg/day

Infants 75 mg/kg/day

Neonates <32 wPCA

Neonates >32 wPCA

PO/PR: 10–15 mg/kg

PO/PR: 15–20 mg/kg

Neonates <32 w.

40 mg/kg/day neonates >32 w.

60 mg/kg/day

IV paracetamol (propacetamol)

Term neonates

Infants and children

7.5 mg/kg q6H

12.5 mg/kg q6H

30 mg/kg/day

max 3.75 g/day

Ibuprofen

Children

Term neonatesa

PO/PR: 5–10 mg/kg q6–8H

PO: 5 mg/kg

q12–24H

<40 mg/kg/day

<30 mg/kg

Ketorolac

Childrena

IV: 0.5 mg/kg q6–8H

<2 mg/kg/day

<5 consecutive days

Sucrose

Preterm neonates

Term neonates

PO 24 % solution:

 0.5 ml

 1 ml

Doses shouldn’t exceed 10/day

Dexamethasone

All ages

IV: 0.1–0.15 mg/kg

Single bolus


wPCA weeks post conceptional age, q every, H hour

aShould be used cautiously <6 months of age and reassessed daily

Non-opioid analgesics could be indicated as a single therapy for mild pain and as adjuvants for moderate to severe pain [60]. The combination of more than one non-opioid analgesic may potentiate their respective efficacy and has shown significant opioid-sparing effects [61]. The early use of non-opioid analgesic adjuvants is associated with reduced risk of serious postoperative opioid adverse events (OAE) [62].


23.4.2.1 Acetaminophen (Paracetamol)


Acetaminophen is a common co-analgesic medication in children. The multiple routes of administration allow an easy adaptation to the patient’s needs. The intravenous route gives more reliable plasmatic levels, bioavailability, and a slightly faster onset time over rectal or oral routes [63].

Acetaminophen exerts its analgesic effects through the inhibition or prostaglandin release, as a cannabinoid ligand, enhancing inhibitory descending pathways by serotoninergic interactions [64]. The administration of acetaminophen is safe in neonates as far as doses are lowered by 50 % taking in account the longer half-life (up to 7 h).


23.4.2.2 NSAIDs


NSAIDs analgesic effects are mediated by the inhibition of COX-1 and COX-2 activity. As a group, they inhibit the biosynthesis of prostaglandins with the subsequent reduction of excitatory amino acids [65]. Due to its opioid-sparing effects, NSAIDS are effective for the reduction of opioid-induced adverse effects [61, 66]. NSAIDS are useful for the prevention of pain rebound during weaning from regional analgesia. Parents should be taught to give NSAIDS (and acetaminophen) before wearing off a regional block [67].

Inadequate pain relief has been associated with the fear of opioids’ adverse effects at home. The association of oral ibuprofen 10 mg/kg every 8 h and oral acetaminophen 10–15 mg/kg every 6 h provided similar analgesia than PO morphine, with less respiratory adverse effects in children undergoing tonsillectomy [68]. It is possible that with adequate information, parents would have a better adherence to the postoperative pain programmes with non-opioid-based analgesic plan.

Ketorolac is commonly used intravenously, and more recently, the intranasal route has also been described [69]. Even if it has been safely used in infants, the lower age limit is still under debate. The administration of ketorolac 0.5 mg/kg every 6–8 h was associated with a 17 % incidence of bleeding events (fresh blood in tubes, surgical wound or intra-abdominal bleeding, blood-positive stools) in small infants (average 21 days) [70].

Only gold members can continue reading. Log In or Register to continue

Sep 22, 2016 | Posted by in ANESTHESIA | Comments Off on Acute Pain Management and Prevention

Full access? Get Clinical Tree

Get Clinical Tree app for offline access